SCHEMBL905306

SCHEMBL905306

NC1C2CC3CC(C2)CC1(C(=O)O)C3

nearest known ligand 0.39

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
THRB P10828 1/20 0.39
CYP2C9 P11712 1/20 0.39
EPHX1 P07099 2/20 0.34
EPHX2 P34913 1/20 0.34
ALDH1A1 P00352 4/20 0.34
TSHR P16473 2/20 0.34
ALOX15 P16050 1/20 0.33
HSD11B1 P28845 1/20 0.33
GRM5 P41594 4/20 0.32
GRM2 Q14416 4/20 0.32
GRM6 O15303 2/20 0.32
GRM1 Q13255 2/20 0.32
GRM4 Q14833 2/20 0.32
GRM3 Q14832 1/20 0.32
SLC22A2 O15244 1/20 0.32
SLC22A1 O15245 1/20 0.32
GRIN2D O15399 1/20 0.32
GRIN3B O60391 1/20 0.32
LMNA P02545 1/20 0.32
NFKB1 P19838 1/20 0.32

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5243807 0.83 ALDH1A1 (0.38) THRBCYP2C9EPHX1EPHX2ALDH1A1
Hydrochloric Acid SCHEMBL29663474 0.78 GRM4 (0.34) CYP2C9ALDH1A1ALOX15GRM5GRM2
SCHEMBL11344046 0.77 ALDH1A1 (0.42) EPHX1EPHX2ALDH1A1TSHRNPC1
SCHEMBL59961 0.77 CYP2C9 (0.36) THRBCYP2C9EPHX1EPHX2ALDH1A1
Hydrochloric Acid SCHEMBL11330580 0.76 ALDH1A1 (0.41) EPHX1EPHX2ALDH1A1TSHRNPC1
SCHEMBL26963220 0.76 CYP2C9 (0.39) THRBCYP2C9EPHX1EPHX2ALDH1A1
Bicarbonate SCHEMBL905261 0.75 THRB (0.39) THRBCYP2C9EPHX1EPHX2ALDH1A1
SCHEMBL1072000 0.75 THRB (0.35) THRBCYP2C9EPHX1EPHX2ALDH1A1
SCHEMBL74823 0.75 THRB (0.35) THRBCYP2C9EPHX1EPHX2ALDH1A1
SCHEMBL1088728 0.75 THRB (0.35) THRBCYP2C9EPHX1EPHX2ALDH1A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 38 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20250361280-A1 CONJUGATED HEPCIDIN MIMETICS PROTAGONIST THERAPEUTICS INC (US) 2025-11-27 US claimed
EP-4472995-A2 CONJUGATED HEPCIDIN MIMETICS Protagonist Therapeutics, Inc. (US) 2024-12-11 EP claimed
WO-2023150618-A2 CONJUGATED HEPCIDIN MIMETICS PROTAGONIST THERAPEUTICS, INC. (US) 2023-08-10 WO claimed
EP-2272825-B1 Protected amino hydroxy adamantane carboxylic acid and process for its preparation ASTRAZENECA AB (SE) 2015-11-04 EP claimed
WO-2013111158-A2 PROCESS FOR THE PREPARATION OF DPP-IV INHIBITOR MSN LABORATORIES LIMITED (IN) 2013-08-01 WO claimed
EP-2272825-A2 N-Protected amino hydroxy adamantane carboxylic acid and process for its preparation Bristol-Myers Squibb Company (US) 2011-01-12 EP claimed
CN-101747221-A Method for preparing amino adamantane carboxylic acid compounds UNIV GUANGDONG TECHNOLOGY 2010-06-23 CN claimed
EP-1559710-A2 Cyclopropyl-fused pyrrolidine-based inhibitors of dipeptidyl peptidase IV, process for their preparation and their use Bristol-Myers Squibb Company (US) 2005-08-03 EP claimed
US-20260078095-A1 NEUROTENSIN RECEPTOR LIGANDS 3B PHARMACEUTICALS GMBH (DE) 2026-03-19 US disclosed
US-20250361280-A1 CONJUGATED HEPCIDIN MIMETICS PROTAGONIST THERAPEUTICS INC (US) 2025-11-27 US disclosed
EP-4472995-A2 CONJUGATED HEPCIDIN MIMETICS Protagonist Therapeutics, Inc. (US) 2024-12-11 EP disclosed
WO-2023150618-A2 CONJUGATED HEPCIDIN MIMETICS PROTAGONIST THERAPEUTICS, INC. (US) 2023-08-10 WO disclosed
EP-3712131-B1 NEUROTENSIN RECEPTOR LIGANDS 3B PHARMACEUTICALS GMBH (DE) 2023-02-01 EP disclosed
CN-109320502-B Neurotensin receptor ligands 3B制药有限公司 2022-06-07 CN disclosed
CN-101747221-A Method for preparing amino adamantane carboxylic acid compounds UNIV GUANGDONG TECHNOLOGY 2010-06-23 CN disclosed
CN-101747221-A Method for preparing amino adamantane carboxylic acid compounds UNIV GUANGDONG TECHNOLOGY 2010-06-23 CN disclosed
US-20080275112-A1 Invention Concerning Aminoadamantane Compounds SCHREINER PETER R 2008-11-06 US disclosed
EP-1751108-A1 ADAMANTYL-ACETAMIDE DERIVATIVES AS INHIBITORS OF THE 11-BETA-HYDROXYSTEROID DEHYDROGENASE TYPE 1 ENZYME ABBOTT LABORATORIES (US) 2007-02-14 EP disclosed
WO-2005108368-A1 ADAMANTYL-ACETAMIDE DERIVATIVES AS INHIBITORS OF THE 11-BETA-HYDROXYSTEROID DEHYDROGENASE TYPE 1 ENZYME ABBOTT LABORATORIES (US) 2005-11-17 WO disclosed
US-4273704-A N-Adamantane-substituted tetrapeptide amides G. D. SEARLE & CO. (US) 1981-06-16 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20250361280-A1 CONJUGATED HEPCIDIN MIMETICS HAMP, VIP, HDGF THRB 910/4885CYP2C9 2209/4885EPHX1 2087/4885
US-20080275112-A1 Invention Concerning Aminoadamantane Compounds GABRA5, GABRA1, GABRA4 THRB 2133/4885CYP2C9 2030/4885EPHX1 1850/4885
US-20260078095-A1 NEUROTENSIN RECEPTOR LIGANDS NTSR1, NTSR2, GRPR THRB 364/4885CYP2C9 4294/4885EPHX1 2859/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.